The popular edible mushroom Ganoderma lucidum (Reishi) has been widely used for the general promotion of health and longevity in Asian countries. The dried powder of Ganoderma lucidum was popular as a cancer chemotherapy agent in ancient China. The authors recently demonstrated that Ganoderma lucidum inhibits constitutively active transcription factors nuclear factor kappa B (NF-κB) and AP-1, which resulted in the inhibition of expression of urokinasetype plasminogen activator (uPA) and its receptor uPAR. Ganoderma lucidum also suppressed cell adhesion and cell migration of highly invasive breast and prostate cancer cells, suggesting its potency to reduce tumor invasiveness. Thus, Ganoderma lucidum clearly demonstrates anticancer activity in experiments with cancer cells and has possible therapeutic potential as a dietary supplement for an alternative therapy for breast and prostate cancer. However, because of the availability of Ganoderma lucidum from different sources, it is advisable to test its biologic activity.
indirectly, via the activation of the immune response of the host organism by the stimulation of natural killer cells, T cells, B cells, and macrophagedependent immune system responses.
14 Polysaccharides isolated from the fresh fruiting body of Ganoderma lucidum (PS-G) stimulated production of interleukin (IL)-1β, tumor necrosis factor (TNF)-α, and IL-6 from human monocyte-macrophages and interferon (IFN)-γ from T lymphocytes. 15 Furthermore, these PS-G-induced cytokines suppressed the proliferation and clonogenicity of human leukemic cells. 15 PS-G also enhanced the immune responses and elicited antitumor effects from human neutrophils by inhibiting spontaneous and Fas-mediated apoptosis through the activation of the phosphatidylinositol (PI) 3-kinase/Akt pathway. 16 In addition, PS-G enhanced phagocytic activity of neutrophils through the mitogen-activated protein kinase (MAPK) and protein kinase C (PKC) pathways. 17 Finally, polysaccharides from Ganoderma lucidum demonstrated a chemopreventive effect, which was mediated by the induction of glutathione S-transferase (GST) activity. 18 
Saccharide-Containing Fractions
The aminopolysaccharide fraction (G009) from Ganoderma lucidum demonstrated the inhibition of reactive oxygen species, which have been implicated in the pathophysiology of cancer. 19 G009 inhibited iron-induced lipid peroxidation and inactivated hydroxyl radicals and superoxide anions. 20 Furthermore, G009 also reduced oxidative DNA damage, suggesting that the aminopolysaccharide fraction of Ganoderma lucidum possesses chemopreventive potential. 20 A fucose-containing glycoprotein fraction from the water-soluble extracts of Ganoderma lucidum stimulated spleen cell proliferation and cytokine expression. 21 Although the active fraction contained the majority of D-glucose, D-mannose, and D-galactose, the only active component was identified in the glycopeptide fraction containing fucose residues. In addition, the crude extract of Ganoderma lucidum did not stimulate expression of cytokines, whereas glycoprotein fraction significantly induced the expression of IL-1, IL-2, and interferon (IFN)-γ. 21 A proteoglycan isolated from the fruiting body of Ganoderma lucidum (GLIS) is predominantly composed of D-glucose, D-galactose, and D-mannose in a carbohydrate:protein ratio 11.5:1. 22 GLIS stimulated the proliferation and activation of B lymphocytes, resulting in the increased production of IL-2, whereas the secretion of IL-4 was not changed. Furthermore, GLIS also enhanced the expression of PKCα and PKCγ in B cells. 22 Two cerebrosides, glycosphingolipids consisting of D-glucose, sphingosine, and 2-hydroxypalmitoyl or 2-hydroxystearoyl fatty acid moiety, respectively, were isolated from the fruiting body of Ganoderma lucidum. 23 Interestingly, both cerebrosides inhibited DNA polymerases, suggesting their possible use for cancer therapy by inhibiting DNA replication.
Triterpenes
More than 100 highly oxygenated and pharmacologically active lanostane-type triterpenes have been isolated from Ganoderma lucidum. 24 Some of these triterpenes, isolated more than 20 years ago and originally named ganoderic acids U, V, W, X, and Y, demonstrated cytotoxicity against hepatoma cells in vitro. 25 More recently, ganoderic acids A and C inhibited farnesyl protein transferase, an enzyme that is crucial for activation of the Ras oncoprotein responsible for cell transformation. 2 6 Furthermore, new triterpenes isolated from the spores of Ganoderma lucidum were tested for their cytotoxicity against mouse sarcoma (Meth-A) and mouse Lewis lung carcinoma (LLC) cells. The ganoderic alcohols lucidimols A and B, ganodermanondiol, ganoderiol F, and ganodermanontriol demonstrated cytotoxic effects on both tumor cell lines. [27] [28] [29] However, the new isolated ganoderic acids γ, δ, ε, ζ, η, and θ did not show any activity against cancer cells.
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The triterpenoid fraction of the fruiting body of Ganoderma lucidum inhibited primary solid-tumor growth in the spleen, liver metastasis, and secondary metastatic tumor growth in the liver, which were originally induced by the intrasplenic implantation of the LLC in mice. 30 In addition, the triterpenoid fraction inhibited Matrigel-induced neovascularization, and the biologically active compound responsible for the inhibition of angiogenesis was identified as ganoderic acid F. 30 
Phenols isolated by the methanolic extraction from
Ganoderma lucidum demonstrated antioxidant activity in the inhibition of lipid peroxidation, which was comparable to the antioxidant activity of phenols isolated from Ganoderma tsugae. 31 Lipids extracted from the germinating spores of Ganoderma lucidum remarkably inhibited the growth of mouse hepatoma, sarcoma S-180, and reticulocyte sarcoma L-II cells in mouse, suggesting that the biological activity of Ganoderma lucidum could be enhanced by the germination of dormant spores.
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Signaling Pathways
Ganoderma lucidum is available as a dietary supplement in the form of spores, fruiting body, or water or alcohol extracts. Although the identification of biologically active components of Ganoderma lucidum is important for characterizing their specific activity, some of these components can be toxic. Furthermore, certain components in the herbal products can reduce the cytotoxicity of the whole product, and the interaction between different biologically active compounds can increase their effects. 33 Therefore, some studies demonstrated the effect of the whole product or the unfractionated extracts from Ganoderma lucidum on specific signaling pathways in cancer cells.
One of the characteristics of highly metastatic cancer cells is the constitutive activation of transcription factors AP-1 and NF-κB. We have shown that the inhibition of AP-1 and NF-κB results in the suppression of secretion of urokinase-type plasminogen activator (uPA) following the inhibition of cell migration of highly invasive breast cancer cells. 34, 35 By using commercially available dietary supplements in the form of spores (GS) and fruiting body (GFB) of Ganoderma lucidum, we have recently demonstrated that Ganoderma lucidum inhibits constitutively active AP-1 and NF-κB in highly invasive breast and prostate cancer cells. 36 Furthermore, both GS and GFB downregulated the expression of uPA and its receptor uPAR as well as secretion of uPA, resulting in the inhibition of cell motility of breast and prostate cancer cells. 36 In addition, Ganoderma lucidum also suppressed cell adhesion to fibronectin (FN), which binds to the α 3 β 1 integrin receptor, and to vitronectin (VN), which binds to the α V β 3 integrin receptor (Figure 1 ). Our data suggest that Ganoderma lucidum inhibits the formation of uPAuPAR-FN-α 3 β 1 and uPA-uPAR-VN-α V β 3 complexes, resulting in the inhibition of cell adhesion and cell motility of highly invasive breast and prostate cancer cells (Figure 2 ). Therefore, we propose the mechanism (on the molecular level) by which Ganoderma lucidum inhibits invasion and metastasis of breast and prostate cancers.
An alcohol extract of Ganoderma lucidum inhibited proliferation of breast cancer cells by cell-cycle arrest at the G1 phase of the cell cycle by upregulating the cell-cycle inhibitor p21/Waf-1 and by downregulating cyclin D1. 37 Furthermore, the alcohol extract also induced apoptosis of breast cancer cells, which was mediated through the upregulation of expression of proapoptotic Bax protein. 37 A triterpene-enriched extract of Ganoderma lucidum inhibited growth of hepatoma cells but not a normal human liver cell line. 38 The inhibitory effect was caused by a decrease in the activity of PKC and activation of the c-Jun N-terminal kinase (JNK) and p38 MAPK, resulting in G2 cellcycle arrest. 38 A water extract from Ganoderma lucidum induced the neuronal differentiation and prevented apoptosis of rat pheochromocytoma PC12 cells derived from a tumor of adrenal medulla, suggesting the presence of neuroactive compounds in Ganoderma lucidum. 39 These effects were probably mediated through the ras/extracellular signal-regulated kinase (Erk) and cAMP-response element binding protein (CREB) signaling pathways because Ganoderma lucidum induced activation of Erk1, Erk2, and CREB. 39 Taken together, the antitumor activity of Ganoderma lucidum is caused by the inhibition or activation of specific mechanisms and pathways ( Table 2 ). As mentioned above, some of the effects on cancer cells are indirect and are caused by stimulation of the immune system by polysaccharides and the release of cytokines from activated macrophages and T lymphocytes. 15 Other effects of Ganoderma lucidum are targeted directly to the cancer cells by modulating their intracellular signaling and can affect the behavior of cancer cells.
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The Sources of Ganoderma lucidum and Its Biological Activity
The usefulness of the edible mushroom Ganoderma lucidum as a preventive/therapeutic dietary supplement has been justified in TCM for thousands of years and has recently gained some interest also in Western medicine. However, because Ganoderma lucidum is currently available from different sources and because the quality and composition are unknown and not characterized, the biological effect of Ganoderma lucidum on cancer cells can be variable. Therefore, we have compared the activity of some of the samples of Ganoderma lucidum that are available in the form of dietary supplements. Because we have recently demonstrated that the potency to inhibit cancer cell migration is directly linked to the inhibition of constitutively active NF-κB, we evaluated the potency of fruiting body, spores, and their mixture to inhibit NF-κB and migration of highly invasive breast and prostate cancer cells. 40 Although our data demonstrated that Ganoderma lucidum inhibits breast and prostate cancer cells with the same potency, suggesting the involvement of common signaling pathways, the composition of tested samples did not correlate with their inhibitory activity. 40 For example, the dietary supplements containing spores of Ganoderma lucidum, which are usually more expensive than the supplements containing the ground mushroom (fruiting body), demonstrated diverse inhibitory activity, and one sample containing fruiting body was more active than another containing spores (Table 3) . Because the biological activity of the dietary supplement Ganoderma lucidum reflects the concentration of the active ingredients, which are variable and dependent on the harvesting, age, manipulation, and storage of mushrooms and spores, it is advisable to test each new sample for its biological activity. For example, the contents of triterpenes and their compositions isolated from Ganoderma lucidum varied among the specimen obtained from different strains, cultivating areas (China, Vietnam, Japan, or Korea), or mushroom forms. 41 Furthermore, because the dietary supplements are not approved or regulated by the Food and Drug Administration (FDA), some of them can be without any effect because the producers of dietary supplements do not have to provide the evidence that the FDA relies on to substantiate safety or effectiveness of a product or substance. 42 However, we and others have clearly demonstrated the anticancer activity of the dietary supplement Ganoderma lucidum at the molecular and cellular levels.
Summary and Future Directions
The chemopreventive and therapeutic studies in Asia have demonstrated the effect of herbal supplements on different diseases, including cancer. The popular edible mushroom Ganoderma lucidum has been used mainly against cancer and linked to lower rates of mortality. Scheme depicting the role of Ganoderma lucidum in the inhibition of a uPA-uPAR-integrin complex. Urokinase plasminogen activator (uPA) binds to uPA receptor (uPAR) and forms a complex with α V β 3 integrin, which binds vitronectin (VN). uPA and uPAR can also form the complex with α 3 β 1 integrin, which binds fibronectin (FN). Ganoderma lucidum inhibits constitutively active AP-1 and NF-κB, resulting in the inhibition of expression of uPA and uPAR and secretion of uPA. The impaired formation of VN-α V β 3 -uPA-uPAR and FN-α 3 β 1 -uPA-uPAR will result in the inhibition of cell adhesion and cell migration of breast and prostate cancer cells. NF-κB = nuclear factor κB; AP-1 = activator protein-1; uPA = urokinase plasminogen activator; uPAR = uPA receptor; PKC = protein kinase C; JNK = c-Jun N-terminal kinase; MAPK = mitogen-activated protein kinase; Erk = ras/extracellular signal-regulated kinase; CREB = camp-response element binding protein.
responsible for aberrant characteristics of cancer cells were modulated by Ganoderma lucidum, resulting in cell-cycle arrest, induction of apoptosis, inhibition of growth, and suppression of metastatic behavior. Ganoderma lucidum also inhibits constitutively active transcription factors NF-κB and AP-1, which were suggested as potential therapeutic targets for cancer treatment. 43, 44 Because NF-κB controls the expression of proteins involved in cell adhesion, migration, and invasion (uPA, uPAR) 45, 46 ; proteins protecting against cell death (Bcl-2, Bcl XL ) 47 ; oncoproteins stimulating dysregulation of the cell cycle and tumor formation (cyclin D1) 48 ; and angiogenic factors that stimulate tumor growth (VEGF, FGF2, TGF-β, MMP-9, and COX-2), 49 the inhibition of NF-κB by Ganoderma lucidum is especially important for the prevention and treatment of cancer. Moreover, this dietary supplement has the potential to be used, after evaluation in animal and clinical studies, as an adjuvant to the systematic therapy against cancer. 
